Fred Hutch researchers played a pivotal role in developing vaccines that prevent infections that cause cervical cancer, and are pursuing more innovative treatments:
Developing the HPV Vaccine - Dr. Denise Galloway and colleagues made discoveries that led to Gardasil and Cervarix, the two vaccines that have been found to prevent HPV infection in women. Gardasil, approved for use in the U.S. in 2006, prevents the types of HPV that account for 70 percent of cervical cancers and 90 percent of genital warts. Cervarix is licensed for use in Europe. Learn more >
New research shows that the HPV vaccine may do more than just prevent cervical cancer. Because HPV is now linked to anal, vaginal, vulvar and penile cancers, as well as cancer of the oropharynx (the middle part of the throat including the soft palate, the base of the tongue, and the tonsils), the vaccine is even more effective in preventing cancer than first thought.
Unraveling genes' role in cervical cancer – Research by Dr. Margaret Madeleine and colleagues found that certain gene variants may lead to cervical cancer in women infected with HPV. By analyzing immune-system genes of women with and without cervical cancer, researchers found evidence that certain gene variants may affect women's cancer risk. The discovery may help explain why only a small proportion of women infected with HPV's cancer-causing form aquire the disease, and may accelerate the pursuit of new treatments. Learn more >
Reducing cancer worldwide - Nearly a quarter of the world’s cancers are caused by infectious diseases that are preventable or treatable, which include lymphoma from Epstein-Barr virus, sarcomas associated with HIV, cervical cancer from human papillomavirus and liver cancer from hepatitis B and C. To reduce the burden of cancer worldwide, Fred Hutch has united with the Uganda Cancer Center to open a new state-of-the-art research, training and clinical care facility—UCI-Fred Hutch Cancer Centre— a major milestone.
Learn more >